Expression data of multiple sclerosis patients receiving subcutaneous Interferon-beta-1a therapy [U133 Plus 2.0]

ABSTRACT: The purpose of this study was to characterize the transcriptional effects induced by subcutaneous IFN-beta-1a treatment (Rebif, 22 µg or 44 µg three times a week) in patients with relapsing-remitting form of multiple sclerosis (MS). By using Affymetrix DNA microarrays, we obtained genome-wide expression profiles of peripheral blood mononuclear cells from 12 MS patients within the first two years of IFN-beta administration.

ORGANISM(S): Homo sapiens

PROVIDER: GSE33464 | GEO | 2011/12/06

SECONDARY ACCESSION(S): PRJNA148781

REPOSITORIES: GEO